Activity
14K followers
-
Marc de Garidel shared thisAs part of our full year announcement, I wanted to separately address my big thanks to the Sofinnova team for supporting Abivax since 2019 & in particular Kinam Hong. Kinam has been the architect with Didier Blondel, our CFO, of various critical financings in late 22 & early 23 which allowed the arrival of first class US investors & our successful IPO in late 2023. Kinam was the person to convince me to join Abivax as CEO & chairman of the company at the time I was planning to retire. This has been an incredible journey together & we are so thankful to you for helping us develop a potential great drug for IBD patients.Marc de Garidel shared thisToday Abivax shared our full year 2025 financial results and provided business updates. Updates include: 📢 Positive ABTECT-UC Phase 3 Data Safety Monitoring Board meeting results 📢 Pivotal ABTECT-UC maintenance trial remains on track for topline results in late Q2 2026 📢 Michael Nesrallah, MBA is appointed Chief Commercial Officer, along with other key senior leadership hires Read more in our press release: https://lnkd.in/gpse646N
-
Marc de Garidel shared thisWe are happy to report our solid cash position to continue to develop obefazimob as a potential leader in the IBD field. Our UC phase 3 maintenance readout is approaching at the end of the next quarter, our safety remains strong as attested by the DSMB & we are bringing great new talents such as Michael Nesrallah to prepare for a US potential launch in 2027. Thanks to the Abivax team for advancing our various programs & we are looking forward to the very exciting readout in UC very soon. Stay tuned.Marc de Garidel shared thisToday Abivax shared our full year 2025 financial results and provided business updates. Updates include: 📢 Positive ABTECT-UC Phase 3 Data Safety Monitoring Board meeting results 📢 Pivotal ABTECT-UC maintenance trial remains on track for topline results in late Q2 2026 📢 Michael Nesrallah, MBA is appointed Chief Commercial Officer, along with other key senior leadership hires Read more in our press release: https://lnkd.in/gpse646N
-
Marc de Garidel shared thisThanks to the Abivax team for an amazing ECCO participation where obefazimod was featured in 6 oral presentations & in 22 abstracts. Beyond the quantity, the excitement lied around the potential of the drug to not only address inflammation in IBD but also fibrosis which no commercial drug does simultaneously today.Marc de Garidel shared thisToday, Abivax shared data from 22 abstracts evaluating obefazimod in #UlcerativeColitis and #CrohnsDisease at #ECCO2026. The presentations included results from longer-term clinical experience with obefazimod, providing additional insight into its safety profile over extended treatment durations, as well as data exploring the durability of treatment effect in maintenance settings. In addition, new preclinical findings were presented showing initial evidence of anti-fibrotic activity, further expanding understanding of obefazimod’s potential impact on #IBD pathophysiology. Collectively, the data shared at ECCO contribute to the growing body of evidence supporting obefazimod’s first-in-class microRNA-based approach and its continued evaluation in IBD. Read more in our press release: https://bit.ly/3ZJKHjr
-
Marc de Garidel shared thisExciting times for Abivax at ECCO with 22 abstracts accepted for obefazimod. Stay tuned!Marc de Garidel shared thisAs #ECCO2026 approaches, we look forward to sharing a broad body of scientific data on obefazimod in #InflammatoryBowelDisease, including #UlcerativeColitis and #CrohnsDisease. Abivax will present 22 accepted abstracts at this year’s Congress, spanning multiple sessions and formats. The presentations reflect the depth and consistency of the obefazimod clinical and preclinical programs, including new insights into its potential anti-fibrotic properties. We invite attendees to engage with the upcoming oral and poster presentations and to connect with members of our team onsite to discuss the data and its potential implications for patients living with #IBD. Learn more about the accepted abstracts in our press release: https://bit.ly/4rV6GQr
-
Marc de Garidel shared thisGreat initiative from Sofinnova Partners to support the life sciences industry in Europe by creating this coalition to help scale biotech companies.Marc de Garidel shared this𝗞𝗲𝗲𝗽𝗶𝗻𝗴 𝗘𝘂𝗿𝗼𝗽𝗲 𝗮𝘁 𝘁𝗵𝗲 𝗳𝗼𝗿𝗲𝗳𝗿𝗼𝗻𝘁 𝗼𝗳 𝗹𝗶𝗳𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝘀𝘁𝗮𝗿𝘁𝘀 𝘄𝗶𝘁𝗵 𝗯𝗮𝗰𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗼𝗿𝘀 𝘄𝗵𝗼 𝗽𝗼𝘄𝗲𝗿 𝗶𝘁. 🙌 That’s why we’re excited to spearhead the newly launched European Life Sciences Coalition, alongside other leading European VCs, and Invest Europe, to mobilize more private and public investment into Europe’s life sciences and biotech ecosystem. Sofinnova's Cédric Moreau, will serve as the Chair of the Coalition’s Oversight Committee, helping drive the agenda to remove structural barriers and unlock long-term growth for European innovation. This is about ensuring that Europe’s scientific excellence translates into globally competitive life sciences companies, supported by deeper capital and coordinated action across the ecosystem. 🔗 Learn more in the link in comments.
-
Marc de Garidel shared thisExciting biotech company that Hervé has brilliantly developed.Marc de Garidel shared thisI recently spoke with PharmaBoardroom about MaaT Pharma’s journey — not just where we are today, but the future we are shaping for microbiome‑based medicine. This article captures the essence of our mission: redefining how we treat complex diseases by embracing the full power of the microbiome as a therapeutic ally. We are still at the beginning of what this field can unlock, and I’m convinced the next decade will transform patient care in ways we can barely imagine today. If you’re interested in the breakthroughs we’ve achieved so far — and in the vision driving our next steps — I invite you to take a look: https://lnkd.in/dER9iEsM MaaT Pharma
-
Marc de Garidel shared thisFun to participate to this French biotech conversation with Paul & managed with art by Nathalie.Marc de Garidel shared this50 épisodes. 50 conversations avec les décideurs qui façonnent la pharma. Pour marquer cette étape, nous avons fait quelque chose de différent. Réunir deux CEO de biotechs françaises à des moments opposés de leur trajectoire. Marc de Garidel, CEO d'Abivax. Biotech cotée Nasdaq, phase 3 en rectocolite hémorragique avec une innovation first-in-class basée sur le micro-ARN 124 qui tempère l'inflammation sur plusieurs voies. Petite molécule orale dans un marché dominé par les injections. Paul Bravetti, CEO de Brenus Pharma. Biotech lyonnaise qui démarre ses essais cliniques. Plateforme d'immunothérapies in vivo qui éduque le système immunitaire du patient pour cibler et détruire les cellules tumorales directement. First-in-class en oncologie. Un dialogue en français. Ancré dans notre culture entrepreneuriale. Pensé pour notre écosystème biotech. Un moment lucide et ambitieux entre deux CEO de biotechs françaises. L'épisode sort lundi. Abonnez-vous pour le recevoir dès sa sortie : https://lnkd.in/er9Htkg4 🎁 Pour les plus impatients, un extrait est disponible dès maintenant : https://lnkd.in/eGj8Msqf Pharma Minds Podcast
-
Marc de Garidel shared thisI was fortunate to kick off the BiotechTV series at JPM & excited to share Abivax promising 2026 year. Thanks Brad for the invitation.Marc de Garidel shared this𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year Full video: https://lnkd.in/eH3-8tra He discusses the company's accomplishments to date, and highlights learnings about the mechanism and important data in 2026 in the maintenance settting for UC and Crohn's later this year. BiotechTV's coverage of SF Healthcare Week is brought to you by HSBC Innovation Banking. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills North America | Evaluate Ltd
-
Marc de Garidel shared thisAfter a remarkable 2025 year for Abivax, we are looking forward to an even more exciting year for patients with major milestones for both our Ulcerative Colitis phase 3 maintenance trial & our Crohn’s disease phase 2B trial. We also strive for scientific leadership in the IBD field as 22 abstracts have been accepted at the next big international gastroenterology congress (ECCO). I want to thank the medical community for their incredible support & the Abivax team for the execution of the work. Happy New Year!Marc de Garidel shared thisToday, Abivax announced its 2026 corporate outlook, highlighting new market insights, clinical progress, and advances in our therapeutic pipeline. Updates include: ☑️ New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD space ☑️ ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on December 18, 2025, found no new safety signals with over 80% of participants having completed the 44-week double blind maintenance trial ☑️ ABTECT-UC Phase 3 maintenance topline results expected late Q2 2026, with a subsequent US regulatory filing planned for late 2026 ☑️ ENHANCE-CD Phase 2b induction trial of obefazimod in moderate-to-severely active Crohn’s disease (CD) ongoing; induction results expected late 2026 ☑️ 22 abstracts accepted for upcoming February 2026 European Crohn’s and Colitis Organization (ECCO) conference including oral presentation of obefazimod impact on fibrosis in in-vitro and preclinical models ☑️ Cash runway expected into Q4 2027, after full debt reimbursement in Q4 2025 The company looks forward to discussing these exciting updates in San Francisco next week. Read more in our press release: https://bit.ly/3L7OOCd
-
Marc de Garidel liked thisMarc de Garidel liked this📣 Dernière ligne droite pour le Prix de la Coopération en Santé 2026 ! Vous portez un projet qui transforme la coopération entre acteurs de santé ? Ce prix est fait pour vous ! 🌟 Pourquoi postuler ? ✅ Une remise de prix par une personnalité lors des États Généraux le 3 juin 2026 (un événement clé que nous organisons ensemble !) ✅ Une visibilité dans Les Échos ou Le Parisien ✅ Une tribune lors des États Généraux 2027 📅 Dépêchez-vous : dossier à envoyer avant le 3 mai 2026 ! 👉 Intéressé(e) ? Contactez-nous sophie.goudal@cooperationsante.fr 🔁 Partagez ce post – vous connaissez forcément un projet inspirant ! 🤳 Abonnez-vous à notre page LinkedIn Coopération Santé pour suivre nos actualités. Plus d’informations sur notre site internet cooperationsante.fr 👀 #CoopérationSanté #Innovation #ÉtatsGénéraux #SantéPublique vincent olivier Marie Josée Augé-Caumon Gérard Mathieu Basile Gorin Agnès Dessaigne Arnaud Jacquier Caroline Blanc-Gatty Emmanuelle Roubertie Eric Vilon Sophie Busquet de Chivré Thomas Ollivier Barbara DE VOS Béatrice NOËLLEC Corinne Fructuoso Voisin Luc Besan��on Hugues FEUTZE NANGUEM Sophélia Picaud Pierre-Frederic Degon Cecile Vandevivere Sophie Goudal
-
Marc de Garidel liked thisMarc de Garidel liked thisBiotechFinances n°1152 est en ligne ! Excellente lecture et très bon week-end à toutes et à tous 🌿 🔜 Le Healthtech Accelerations Summit, c’est le 30 juin prochain à Paris : 👉 www.has-event.com Un grand merci à nos sponsors pour leur soutien 🙏 🏆 Platinum — JEITO | Bpifrance Life Sciences Venture (InnoBio) | France Biotech 🥇 Gold —INITS | Paris Saclay Cancer Cluster (PSCC) | Dechert LLP 🥈 Silver — LCA Audit | BrandSilver | Création & stratégie de marque | Seroba. | LAMY LEXEL Avocats Associés | Fondation Anne et Claude Berda | Région Bourgogne-Franche-Comté | AER BFC | Abivax | Allinvest Securities| Kumaiko
-
Marc de Garidel liked thisMarc de Garidel liked this🌟 ENCORE QUELQUES JOURS ! 🌟 🌟 INSCRIVEZ VOUS A LA SOIREE ANNUELLE ARTCURHOPE - 8 AVRIL 2026 🌟 🔶Charles Pépin, philosophe et écrivain et 🔶Francoise Petrovitch, artiste peintre et sculpteur, nous proposeront un dialogue inédit sur les bienfaits des œuvres d'art originales. Cette soirée sera également l'occasion d'échanger avec vous sur les actions d'ARTCURHOPE - FONDS DE DOTATION au bénéfice des soignants, des malades et des accompagnants autour d'un cocktail. Votre présence est essentielle pour la poursuite de notre mission ! Mille mercis ! 🟠Inscrivez-vous vite, il reste quelques places ! 🟠: https://bit.ly/4afNtTy #lartnoussoigne #lartalhopital #bienetreparlart #lartpourtous #culturealhopital #altruisme #santé #artcontemporain #culture #alliancesanteculture #CharlesPepin #LaureMayoud #lionelnaccache Chantal Piani Karine de Labarthe Fabienne Gachet Volmerange Armand CAIAZZO Arnaud Ameline Alexandre Giuglaris Jérôme de Boisseson Anne de la Roussière Prudhom Anne-Catherine Sylvie Serre
-
Marc de Garidel liked thisIt’s a pleasure to serve as chair for Blood Cancer United’s 2026 Light the Night event in Morris County. We will continue to raise awareness on Hematological diseases and stand with our impacted community members. Calling on our extensive network to join us in making this year’s event extra special!Marc de Garidel liked thisWe are proud to announce that Harout Semerjian, President and CEO of Geron Corporation, will serve as the 2026 Corporate Walk Chair for the Morris County Light The Night. Harout has dedicated his career to advancing innovation in oncology and hematology, with a strong commitment to improving the lives of patients facing serious blood cancers. At Geron that mission includes shining light on lower-risk myelodysplastic syndromes (LR-MDS) – an often underrecognized blood cancer that can profoundly impact patients and their families. Through corporate leadership, partnership, and patient-centered science, Harout and the Geron team are working to bring greater awareness and new possibilities to the blood cancer community. We’re grateful for Harout’s leadership and for Geron’s support of the 2026 Morris County Light The Night as we come together to support patients, families, and lifesaving research. Join us in making a difference by registering for Morris County Light The Night at: https://lnkd.in/esmAKqcb #LightTheNight #BloodCancerUnitedLightTheNight #NewJersey Blood Cancer United
-
Marc de Garidel liked thisExcited to take on this new role at Ipsen—same company, new challenges, same drive!Marc de Garidel liked thisPierrick Lefranc joined Ipsen in 2013, took on his first site in Signes, and never stopped building. On April 1st , he stepped into his role as Executive Vice President of Technical Operations and joined our Executive Leadership Team. 13 years. One company. One more example of what growing from within looks like at Ipsen. 💙 Congratulations, Pierrick. Learn more: https://lnkd.in/epEAKCv8
-
Marc de Garidel liked thisMarc de Garidel liked thisComment apporter aux patients français, les traitements dont ils ont besoin et soutenir et attirer des investissements stratégiques sur notre territoire ? C’est pour répondre à ces enjeux qui sont au cœur du débat public, qu’Ipsen, aux côtés de six laboratoires pharmaceutiques ancrés en France, lance Initiative Pharma : une nouvelle voix syndicale engagée en faveur de l’innovation et de la souveraineté sanitaire. La France représente pour Ipsen, non seulement ses racines, mais aussi son cœur stratégique avec : 👉 son siège social à Paris et ses sites de Signes (Var) et de Dreux (Eure et Loir), 👉 30% de ses collaborateurs, 👉 40 % des dépenses en R&D, 👉 Plus de 50 % de la production de nos médicaments. Dans un contexte où l’accès aux traitements innovants est fragilisé, il est temps de porter une ambition collective : garantir aux patients l’accès aux traitements dont ils ont besoin et soutenir la production et la recherche françaises. Pour en savoir plus sur Initiative Pharma et découvrir ses propositions : www.initiative-pharma.fr
-
Marc de Garidel liked thisMarc de Garidel liked thisTrès heureuse d'avoir lancé ce jeudi le nouveau syndicat Initiative Pharma, aux côtés des laboratoires Sanofi, LFB, Guerbet, Pierre Fabre, Servier et Théa Pharma. Une nouvelle voix syndicale, engagée en faveur de l’innovation et de la souveraineté sanitaire. Initiative Pharma porte trois axes de propositions fortes pour garantir une souveraineté sanitaire durable au service des patients : 1. Intégrer des critères de souveraineté et valoriser l'investissement en France à chaque étape de la décision publique du parcours du médicament 2. Créer une enveloppe dédiée à la souveraineté sanitaire et à l’innovation 3. Instaurer une loi de programmation en santé pour la souveraineté sanitaire et l'innovation Dans un contexte où les États-Unis et la Chine font de la santé une priorité stratégique, il est temps d’agir. Nous appelons à des décisions politiques claires qui soutiennent plus fortement l’innovation et la production française. Le lancement d’Initiative Pharma marque une nouvelle étape en ouvrant le dialogue avec les pouvoirs publics et l’ensemble des acteurs du système de santé. Nous continuerons de porter des propositions ambitieuses pour garantir une souveraineté sanitaire durable. Charles Wolf, Pierre BOYER, Vincent Guiraud-Chaumeil, Ivan Perrichon, Gilles Messal, Didier Véron, Patrice Carayon, Antoine Bernasconi, Frédéric Girard, Eric Ducournau, Karim Boussebaa, Pierre Boulud, Jacques Brom, Jean-Frédéric Chibret, Audrey Duval, MD, Olivier Laureau, Alexandre Merieux, David Loew
-
Marc de Garidel liked thisMarc de Garidel liked thisFighting antimicrobial resistance (AMR) as an investment opportunity? I participated this week to the successful “première” of the HealthCare Investors Meeting in Genolier Innovation Hub bringing together a select group of ten listed and private healthcare companies. A striking signal: three companies - including OM Pharma - were addressing, from different angles, the growing challenge of antimicrobial resistance (AMR). This convergence reflects a broader shift. As our environments become more urban, sanitized and less biodiverse, reduced microbial exposure is contributing to rising rates of infections, AMR, and immune-mediated conditions such as asthma and allergies. At OM Pharma, we address this through bacterial lysates which offer a pragmatic way to train the immune system and act upstream, before infections escalate and require antibiotics. Today more than ever, there is an urgent need for alignment between science, clinical practice and public health priorities around prevention. And clear takeaway: AMR is no longer a niche topic, it is becoming a central healthcare and investment theme. Congrats to Bjoern Zern of schweizeraktien.net AG for organizing and to Frédéric Lelièvre of AGEFI, Nouvelle Agence Économique et Financière for a skillful moderation. And thanks to Antoine Hubert and Anna Gräbner for hosting this great event, always a pleasure to be at the GIH! #OMPharma #AMR #Prevention #Immunology #Pharma #Investing Photos: Sandra Blaser/schweizeraktien.net
-
Marc de Garidel liked thisMarc de Garidel liked this✨ Très fier que le LFB soit membre fondateur d’Initiative Pharma ! 🚀 Nous devons changer de logiciel, la France doit voir la santé comme un investissement vital pour notre souveraineté sanitaire, au même titre que la défense ou l'énergie. 🔬 Investir dans la santé et dans le médicament, c’est préparer l’avenir et garantir à la France une place de leader européen de l’innovation thérapeutique, dans un contexte de compétition internationale accrue. ➡️ 𝐍𝐨𝐮𝐬 𝐚𝐯𝐨𝐧𝐬 𝐭𝐨𝐮𝐬 𝐥𝐞𝐬 𝐚𝐭𝐨𝐮𝐭𝐬 𝐞𝐧 𝐅𝐫𝐚𝐧𝐜𝐞 - 𝐥𝐚 𝐬𝐜𝐢𝐞𝐧𝐜𝐞, 𝐥𝐞𝐬 𝐭𝐚𝐥𝐞𝐧𝐭𝐬, 𝐥𝐞𝐬 𝐢𝐧𝐟𝐫𝐚𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞𝐬 - 𝐩𝐨𝐮𝐫 𝐪𝐮𝐞 𝐝𝐞𝐦𝐚𝐢𝐧 𝐥𝐚 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐝𝐞 𝐦𝐞́𝐝𝐢𝐜𝐚𝐦𝐞𝐧𝐭𝐬 𝐢𝐧𝐧𝐨𝐯𝐚𝐧𝐭𝐬 𝐬𝐞 𝐟𝐚𝐬𝐬𝐞 𝐬𝐮𝐫 𝐧𝐨𝐭𝐫𝐞 𝐭𝐞𝐫𝐫𝐢𝐭𝐨𝐢𝐫𝐞, 𝐚𝐮 𝐛𝐞́𝐧𝐞́𝐟𝐢𝐜𝐞 𝐝𝐞𝐬 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬. Chez Initiative Pharma, nous proposons : ✅ d’intégrer des critères de souveraineté dans toutes les décisions publiques, ✅ de créer une enveloppe budgétaire dédiée à l'innovation et à la souveraineté, ✅ d’instaurer une loi de programmation en santé quinquennale. Bienvenue à Chiesi France, SERB Pharmaceuticals et à France Biotech dans notre nouveau syndicat ! 💪 Je suis convaincu qu’avec l’ensemble des acteurs publics et privés, nous allons contribuer à renforcer notre souveraineté sanitaire au service des patients. Guerbet, Ipsen, les Laboratoires Pierre Fabre, Sanofi, Servier et les Laboratoires Théa. #InitiativePharma #SouverainetéSanitaire #Santé 👉 Plus d'informations ici : https://lnkd.in/e3PP_Wnj
Languages
-
French
-
-
English
-
-
German
-
Organizations
-
IMI
Co-Chairman
- Present -
EFPIA
Vice President
- Present -
G5 Santé
President
- Present -
EBE
President
-
Other similar profiles
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top contentOthers named Marc de Garidel
4 others named Marc de Garidel are on LinkedIn
See others named Marc de Garidel